UCB in Epilepsy and Rare Syndromes
For three decades, we’ve been committed to people living with epilepsy and their families, surrounding the patient and caregiver through every step of their care journey – from diagnosis to treatment to support in helping them navigate those moments in their lives that matter most. Because we must find solutions for seizures that won’t stop, not only to preserve those moments, but to protect the minds and the lives of those living with epilepsy and rare syndromes.
Driven by Patient Value
At our core, we have a profound responsibility to elevate the healthcare ecosystem. It is a responsibility that extends to the very heart of our purpose – patients, and their families. Thirty years ago, we ushered in a new era of epilepsy therapies largely due to our scientific breakthrough, introducing a completely unique and novel mechanism of action in the treatment of epilepsy and, we continued to redefine the SV2A class of medicines to treat seizures.
Commitment to People, Purpose and Science
We will continue to reimage how we care for patients, leveraging today s expertise for a better tomorrow. We are doing so, in many instances, on our own as we look at potential solutions for rapid seizure termination, our work in Developmental and Epileptic Encephalopathies (DEEs), and our pursuits in gene modification. But we understand that with the complexity of the ecosystem, there are instances where we will need to partner with purpose. Therefore, we are also pursuing external research collaborations to validate new potential therapeutic targets. With so much experience behind us and so much potential ahead, we are more invested than ever in profoundly improving the lives of those living with or caring for those with epilepsy or a rare epilepsy syndrome.